The funding for Axonis, which is developing novel medicines for pain and epilepsy, reflects growing confidence in precision ...

BioSpace has been compiling a list of the most innovative and exciting biotechs for a decade. Here we take a look back at ...

Boston-based Seaport Therapeutics closed $225 million in new capital, bringing its total funding to $325 million.

Two Key Executive Hires for Organizational Capabilities and GrowthCAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Anthos ...

Explore our latest breakthroughs in Dementia Associated With Alzheimer’s Disease Research. Learn more about our innovative ...

Sanofi and CD&R entered into exclusive negotiations for the potential sale and purchase of a 50% controlling stake in Opella.

Main Sequence has recruited three healthcare specialists and hopes to expand investments across therapeutics, diagnostics, ...

17:30 EDT C4 Therapeutics (CCCC) files $400M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders ...

Metastasis remains the primary challenge to reducing cancer deaths worldwide. A new MSK study is providing unique insights ...

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501 ...

United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of unique products to address the unmet medical needs of patients with chronic ...

Amplia Therapeutics Ltd. (AU:ATX) has released an update. Amplia Therapeutics Ltd. has announced that its Retail Entitlement Offer is now fully underwritten by Bell Potter Securities Limited and ...